Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors

Nucleus (United States)

Volumn 4, Issue 2, 2013, Pages 142-150

  Adam, Stephen A ^a   Butin Israeli, Veronika ^a   Cleland, Megan M ^a   Shimi, Takeshi ^a   Goldman, Robert D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Farnesylation; Farnesyltransferase inhibitors; Lamins; Senescence

Indexed keywords

LAMIN B; LAMIN B1; LAMIN B2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL NUCLEUS MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GEL ELECTROPHORESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; NUCLEAR LAMINA; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PROCESSING;

FARNESYLATION; FARNESYLTRANSFERASE INHIBITORS; LAMINS; SENESCENCE;

AGING; CELL NUCLEUS; CHILD; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FIBROBLASTS; HUMANS; LAMIN TYPE A; LAMIN TYPE B; NUCLEAR ENVELOPE; NUCLEAR LAMINA; PROGERIA; PROTEIN PRENYLATION;

EID: 84875911766     PISSN: 19491034     EISSN: 19491042     Source Type: Journal    
DOI: 10.4161/nucl.24089     Document Type: Article

References (64)

1. Gonzalez JM, Pla D, Perez-Sala D, Andres V. A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy. [Schol Ed]. Front Biosci (Schol Ed) 2011; 3:1133-46; PMID:21622261; http:// dx.doi.org/10.2741/216.
2. Reddy S, Comai L. Lamin A, farnesylation and aging. Exp Cell Res 2012; 318:1-7; PMID:21871450; http:// dx.doi.org/10.1016/j.yexcr.2011.08.009.
3. Adam SA, Goldman RD. Insights into the differences between the A and B-type nuclear lamins. Adv Biol Regul 2012; 52:108-13; PMID:22119859; http:// dx.doi.org/10.1016/j.advenzreg.2011.11.001.
4. Rusiñol AE, Sinensky MS. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 2006; 119:3265-72; PMID:16899817; http://dx.doi.org/10.1242/jcs.03156.
5. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055; PMID:12702809; http://dx.doi.org/10.1126/sci-ence.1084125.
6. Dechat T, Shimi T, Adam SA, Rusinol AE, Andres DA, Spielmann H P, et al. Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A 2007; 104:4955-60; PMID:17360326; http://dx.doi. org/10.1073/pnas.0700854104.
7. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293-8; PMID:12714972; http://dx.doi.org/10.1038/nature01629.
8. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005; 14:2959-69; PMID:16126733; http://dx.doi. org/10.1093/hmg/ddi326.
9. Toth JI, Yang SH, Qiao X, Beigneux A P, Gelb MH, Moulson CL, et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A 2005; 102:12873-8; PMID:16129834; http://dx.doi. org/10.1073/pnas.0505767102.
10. Mallampalli M P, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005; 102:14416-21; PMID:16186497; http://dx.doi.org/10.1073/pnas.0503712102.
11. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A 2005; 102:10291-6; PMID:16014412; http://dx.doi.org/10.1073/ pnas.0504641102.
12. Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford proge-ria syndrome mutation. J Clin Invest 2006; 116:2115-21; PMID:16862216; http://dx.doi.org/10.1172/ JCI28968.
13. Capell BC, Erdos MR, Madigan J P, Fiordalisi JJ, Varga R, Conneely KN, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005; 102:12879-84; PMID:16129833; http://dx.doi.org/10.1073/pnas.0506001102.
14. Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, Tavarez UL, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A 2008; 105:15902-7; PMID:18838683; http://dx.doi.org/10.1073/pnas.0807840105.
15. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311:1621-3; PMID:16484451; http:// dx.doi.org/10.1126/science.1124875.
16. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2012; 109:16666-71; PMID:23012407; http://dx.doi.org/10.1073/pnas.1202529109.
17. Dalton MB, Fantle KS, Bechtold HA, DeMaio L, Evans RM, Krystosek A, et al. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization. Cancer Res 1995; 55:3295-304; PMID:7614464.
18. Mégnin-Chanet F, Lavelle F, Favaudon V. The farne-syl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution. BMC Pharmacol 2002; 2:2; PMID:11929613; http://dx.doi.org/10.1186/1471-2210-2-2.
19. Kitten G T, Nigg EA. The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. J Cell Biol 1991; 113:13-23; PMID:2007618; http://dx.doi. org/10.1083/jcb.113.1.13.
20. Verstraeten VL, Peckham LA, Olive M, Capell BC, Collins FS, Nabel EG, et al. Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect. Proc Natl Acad Sci U S A 2011; 108:4997-5002; PMID:21383178; http:// dx.doi.org/10.1073/pnas.1019532108.
21. Shimi T, Pfleghaar K, Kojima S, Pack CG, Solovei I, Goldman AE, et al. The A- and B-type nuclear lamin networks: microdomains involved in chromatin organization and transcription. Genes Dev 2008; 22:3409-21; PMID:19141474; http://dx.doi.org/10.1101/ gad.1735208.
22. Burke B, Mounkes LC, Stewart CL. The nuclear envelope in muscular dystrophy and cardiovascular diseases. Traffic 2001; 2:675-83; PMID:11576443; http://dx.doi.org/10.1034/j.1600-0854.2001.21001.x.
23. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2004; 101:8963-8; PMID:15184648; http://dx.doi.org/10.1073/ pnas.0402943101.
24. Taimen P, Pfleghaar K, Shimi T, Möller D, Ben-Harush K, Erdos MR, et al. A progeria mutation reveals functions for lamin A in nuclear assembly, architecture, and chromosome organization. Proc Natl Acad Sci U S A 2009; 106:20788-93; PMID:19926845; http://dx.doi. org/10.1073/pnas.0911895106.
25. Coffinier C, Chang SY, Nobumori C, Tu Y, Farber EA, Toth JI, et al. Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc Natl Acad Sci U S A 2010; 107:5076-81; PMID:20145110; http://dx.doi.org/10.1073/ pnas.0908790107.
26. nd, et al. Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol Biol Cell 2011; 22:4683-93; PMID:21976703; http:// dx.doi.org/10.1091/mbc.E11-06-0504.
27. Kim Y, Sharov AA, McDole K, Cheng M, Hao H, Fan CM, et al. Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells. Science 2011; 334:1706-10; PMID:22116031; http://dx.doi. org/10.1126/science.1211222.
28. Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev 2011; 25:2579-93; PMID:22155925; http:// dx.doi.org/10.1101/gad.179515.111.
29. Young SG, Meta M, Yang SH, Fong LG. Prelamin A farnesylation and progeroid syndromes. J Biol Chem 2006; 281:39741-5; PMID:17090536; http://dx.doi. org/10.1074/jbc.R600033200.
30. Lehner C F, Fürstenberger G, Eppenberger HM, Nigg EA. Biogenesis of the nuclear lamina: in vivo synthesis and processing of nuclear protein precursors. Proc Natl Acad Sci U S A 1986; 83:2096-9; PMID:3515346; http://dx.doi.org/10.1073/pnas.83.7.2096.
31. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack I F, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 2007; 25:3137-43; PMID:17634493; http://dx.doi.org/10.1200/ JCO.2006.09.4243.
32. Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros W P, et al. Phase I and phar-macokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67:455-63; PMID:20972873; http://dx.doi. org/10.1007/s00280-010-1488-5.
33. Varela I, Pereira S, Ugalde A P, Navarro CL, Suárez M F, Cau P, et al. Combined treatment with statins and ami-nobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008; 14:767-72; PMID:18587406; http://dx.doi.org/10.1038/nm1786.
34. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30:609-41; PMID:15531395; http:// dx.doi.org/10.1016/j.ctrv.2004.06.010.
35. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19:6584-93; PMID:11426643; http://dx.doi.org/10.1038/ sj.onc.1204146.
36. Cristofalo VJ, Pignolo RJ. Replicative senescence of human fibroblast-like cells in culture. Physiol Rev 1993; 73:617-38; PMID:8332640.
37. Freund A, Laberge RM, Demaria M, Campisi J. Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell 2012; 23:2066-75; PMID:22496421; http:// dx.doi.org/10.1091/mbc.E11-10-0884.
38. Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A 1992; 89:3000-4; PMID:1557405; http://dx.doi. org/10.1073/pnas.89.7.3000.
39. Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994; 107:61-7; PMID:8175923.
40. Hennekes H, Nigg EA. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci 1994; 107:1019-29; PMID:8056827.
41. Krohne G, Waizenegger I, Höger TH. The conserved carboxy-terminal cysteine of nuclear lamins is essential for lamin association with the nuclear envelope. J Cell Biol 1989; 109:2003-11; PMID:2808518; http:// dx.doi.org/10.1083/jcb.109.5.2003.
42. Lee R, Chang SY, Trinh H, Tu Y, White AC, Davies BS, et al. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet 2010; 19:1603-17; PMID:20106865; http://dx.doi.org/10.1093/hmg/ddq036.
43. nd, Tu Y, Ren S, Andres DA, Spielmann H P, et al. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 2010; 19:2682-94; PMID:20421363; http://dx.doi.org/10.1093/hmg/ ddq158.
44. Rahman-Roblick R, Roblick UJ, Hellman U, Conrotto P, Liu T, Becker S, et al. p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A 2007; 104:5401-6; PMID:17372198; http://dx.doi. org/10.1073/pnas.0700794104.
45. Gerace L, Huber MD. Nuclear lamina at the crossroads of the cytoplasm and nucleus. J Struct Biol 2012; 177:24-31; PMID:22126840; http://dx.doi. org/10.1016/j.jsb.2011.11.007.
46. Zhang YQ, Sarge KD. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J Cell Biol 2008; 182:35-9; PMID:18606848; http://dx.doi.org/10.1083/ jcb.200712124.
47. Gerace L, Blobel G. The nuclear envelope lamina is reversibly depolymerized during mitosis. Cell 1980; 19:277-87; PMID:7357605; http://dx.doi. org/10.1016/0092-8674(80)90409-2.
48. Adolph KW. ADPribosylation of nuclear proteins labeled with [3H]adenosine: changes during the HeLa cycle. Biochim Biophys Acta 1987; 909:222-30; PMID:3040104; http://dx.doi.org/10.1016/0167-4781(87)90081-9.
49. Moulson CL, Go G, Gardner JM, van der Wal AC, Smitt JH, van Hagen JM, et al. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol 2005; 125:913-9; PMID:16297189; http:// dx.doi.org/10.1111/j.0022-202X.2005.23846.x.
50. Yang SH, Andres DA, Spielmann H P, Young SG, Fong LG. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest 2008; 118:3291-300; PMID:18769635; http://dx.doi. org/10.1172/JCI35876.
51. Yang SH, Chang SY, Ren S, Wang Y, Andres DA, Spielmann H P, et al. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum Mol Genet 2011; 20:436-44; PMID:21088111; http://dx.doi. org/10.1093/hmg/ddq490.
52. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000; 6:2318-25; PMID:10873082.
53. Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N. Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl 2001; (Suppl 37): 64-70; PMID:11842430; http://dx.doi.org/10.1002/ jcb.10067.
54. Tsai MY, Wang S, Heidinger JM, Shumaker DK, Adam SA, Goldman RD, et al. A mitotic lamin B matrix induced by RanGTP required for spindle assembly. Science 2006; 311:1887-93; PMID:16543417; http:// dx.doi.org/10.1126/science.1122771.
55. Yang SH, Chang SY, Tu Y, Lawson GW, Bergo MO, Fong LG, et al. Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases. J Lipid Res 2012; 53:77-86; PMID:22039581; http://dx.doi. org/10.1194/jlr.M021220.
56. Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW, et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet 2006; 79:383-9; PMID:16826530; http:// dx.doi.org/10.1086/505885.
57. Yang SH, Chang SY, Yin L, Tu Y, Hu Y, Yoshinaga Y, et al. An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum Mol Genet 2011; 20:3537-44; PMID:21659336; http://dx.doi. org/10.1093/hmg/ddr266.
58. Yoon BC, Jung H, Dwivedy A, O'Hare CM, Zivraj KH, Holt CE. Local translation of extranuclear lamin B promotes axon maintenance. Cell 2012; 148:752-64; PMID:22341447; http://dx.doi.org/10.1016/j. cell.2011.11.064.
59. Sepp-Lorenzino L, Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 1998; 273:20243-51; PMID:9685373; http://dx.doi. org/10.1074/jbc.273.32.20243.
60. Wang Y, Ostlund C, Choi JC, Swayne TC, Gundersen GG, Worman HJ. Blocking farnesylation of the prela-min A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins. Nucleus 2012; 3:452-62; PMID:22895092; http://dx.doi. org/10.4161/nucl.21675.
61. Sinensky M, Fantle K, Dalton M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesyl-ation-dependent protein processing. Cancer Res 1994; 54:3229-32; PMID:8205544.
62. Dreyfuss G, Adam SA, Choi YD. Physical change in cytoplasmic messenger ribonucleoproteins in cells treated with inhibitors of mRNA transcription. Mol Cell Biol 1984; 4:415-23; PMID:6717428.
63. Dimri G P, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92:9363-7; PMID:7568133; http://dx.doi.org/10.1073/pnas.92.20.9363.
64. Yuan J, Wang X, Zhang Y, Hu X, Deng X, Fei J, et al. shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep 2006; 33:43-9; PMID:16636916; http://dx.doi. org/10.1007/s11033-005-3965-1.